Levels of CK18 in ExoQuickTM preparations from prostate cancer patients (n=6) were significantly higher than in healthy control subjects (n=5) (Figure 6C), suggesting that CK18 in EVs could potentially be used as a circulating cancer biomarker. This evidence concerns the gene KRT18 and cancer.